What are ADMA Biologics's profit margins?

Gross margin is 61.3% and operating margin is 42.1%, with a 32.4% net margin.

Where does ADMA Biologics's income statement data come from?

Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

ADMA Biologics ADMA Income Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Total revenue	$510.17M+19.6%	$426.45M+65.2%	$258.22M+67.6%	$154.08M+90.4%
Total cost of revenue	$217.41M+5.1%	$206.9M+22.2%	$169.27M+42.5%	$118.82M+48.9%
Gross profit	$292.77M+33.3%	$219.55M+147%	$88.94M+152%	$35.27M+2,906%
Gross margin	57.4%+5.9pp	51.5%+17.0pp	34.4%+11.6pp	22.9%+21.4pp
Research and development	$4.76M+163%	$1.81M-45.1%	$3.3M-8.7%	$3.61M-0.9%
Selling, general and administrative	$91.58M+23.6%	$74.12M+25.6%	$59.02M+12.5%	$52.46M+22.3%
Selling and marketing	$3.1M+14.8%	$2.7M-18.2%	$3.3M—	——
Compensation and benefits	$20.03M+47.1%	$13.62M+120%	$6.19M—	——
Occupancy and equipment	$2.4M0.0%	$2.4M0.0%	$2.4M—	——
Depreciation and amortization	$7.9M+2.6%	$7.7M+1.3%	$7.6M+963%	$715K0.0%
Goodwill impairment	$0—	$0—	$0—	——
Impairment charges	$0—	$0—	$0—	——
Other operating expenses	$101.32M+25.8%	$80.57M+19.7%	$67.31M-9.8%	$74.63M+25.3%
Total operating expenses	$101.32M+25.8%	$80.57M+19.7%	$67.31M-9.8%	$74.63M+25.3%
Operating income	$191.44M+37.7%	$138.98M+542%	$21.63M+155%	-$39.37M+32.6%
Operating margin	37.5%+4.9pp	32.6%+24.2pp	8.4%+33.9pp	-25.5%+46.6pp
Interest expense	$7.11M-49.0%	$13.93M-44.3%	$25.03M+29.8%	$19.28M+47.7%
Other income (expense), net	-$8.79M+33.8%	-$13.27M+73.4%	-$49.87M-87.9%	-$26.54M-99.9%
Gain (loss) on disposal of assets	-$9K+91.5%	-$106K+41.8%	-$182K—	——
Income before income taxes	$182.66M+45.3%	$125.71M+545%	-$28.24M+57.1%	-$65.9M—
Income tax expense	$35.73M+150%	-$71.96M—	$0—	$0—
Net income	$146.93M-25.7%	$197.67M+800%	-$28.24M+57.1%	-$65.9M+8.0%
Net margin	28.8%-17.6pp	46.4%+57.3pp	-10.9%+31.8pp	-42.8%+45.7pp
Diluted earnings per share	$0.60-26.8%	$0.82+731%	-$0.13+61.8%	-$0.34+33.3%
Basic earnings per share	$0.61-28.2%	$0.85+754%	-$0.13+61.8%	-$0.34+33.3%
Weighted-average shares, diluted	982.9M+1.7%	966.7M+7.1%	902.3M+14.7%	786.5M+52.3%
Weighted-average shares, basic	956.2M+2.9%	928.9M+3.9%	893.9M+13.7%	786.5M+52.3%
APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition	$20.03M+47.1%	$13.62M+120%	$6.19M—	——
Issuance of warrants to purchase common stock	——	——	$5.6M—	——
Amortization Of Debt Discount Premium	$717K-24.6%	$951K-63.3%	$2.59M—	——
Amortization of capitalized software and acquired intangible assets	$146K-62.4%	$388K-46.4%	$724K+1.3%	$715K0.0%
Amortization Of License Revenue	-$143K0.0%	-$143K0.0%	-$143K—	——
Stock options excluded as their inclusion would be anti-dilutive (in shares)	0—	0—	——	——
Business Acquisitions Pro Forma Revenue	——	——	——	——
Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation	——	$53.33M+252%	-$35.17M—	——
Class Of Warrant Or Right Exercised	——	——	——	——
Federal	$21.93M+110%	$10.43M—	$0—	——
Current State And Local Tax Expense Benefit	$2.78M+47.3%	$1.89M—	$0—	——
Federal	$9.38M+113%	-$72.86M—	$0—	——
Deferred taxes	$11.02M+113%	-$84.28M—	$0—	——
State	$1.64M+114%	-$11.42M—	$0—	——
Defined contribution plan costs	$1.7M+13.3%	$1.5M+15.4%	$1.3M—	——
Deposit Received On Net Assets Held For Sale	$1M—	$0—	$0—	——
Effective tax rates	$0.34—	——	——	——
Income taxes at U.S. statutory rate of 21%	78.6%—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent	——	——	——	——
Nontaxable or nondeductible items	——	——	——	——
Excess tax benefits associated with employee equity plans (in percent)	——	——	——	——
Excess tax benefits associated with employee equity plans	-$8M-41.3%	-$5.66M—	$0—	——
State income taxes – net of federal income tax benefit	——	——	——	——
Effective Income Tax Rate Reconciliation, Tax Credit, Percent	——	——	——	——
Gain/(loss) on dispositions, net	-$9K+91.5%	-$106K+41.8%	-$182K+57.4%	-$427K-93.2%
Gain (Loss) on Disposition of Assets	——	——	——	——
Gain On Sale Of Investments	——	——	——	——
Goodwill impairment losses	$0—	$0—	$0—	——
Impairment Of Long Lived Assets Held For Use	$0—	$0—	$0—	——
Income Loss From Continuing Operations Before Income Taxes Domestic	$182.66M+45.3%	$125.71M+545%	-$28.24M—	——
Income Loss From Continuing Operations Before Income Taxes Foreign	$0—	$0—	$0—	——
Income Tax Effect From Specified States Percentage	——	——	——	——
Federal taxes	$17.59M—	——	——	——
Income Tax Paid Federalafter Refund Received Percent	——	——	——	——
Income Tax Paid Net Percent	——	——	——	——
State taxes	$2.09M—	——	——	——
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount	$0+100%	-$87.97M-1,973%	$4.7M—	——
Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount	$38.36M+45.3%	$26.4M+545%	-$5.93M—	——
Nontaxable or Nondeductible items	$2.8M-35.5%	$4.34M+342%	$983K—	——
Effective Income Tax Rate Reconciliation, Other Adjustments, Amount	$616K-28.5%	$862K-15.0%	$1.01M—	——
Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount	$3.83M+139%	-$9.93M-1,202%	-$763K—	——
Income taxes paid	$19.68M—	——	$0—	——
Income Taxes Paid, Net	$19.68M—	——	——	——
Accounts payable	——	$4.15M+8.1%	$3.84M—	——
Accounts payable and other current liabilities	——	——	$86K—	——
Increase (Decrease) in Accounts Receivable	$108.43M—	——	$11.92M—	——
Accrued liabilities	$5.21M+400%	$1.04M-86.2%	$7.53M-0.1%	$7.53M-9.7%
Increase (Decrease) in Deferred Income Taxes	-$11.02M-113%	$84.28M—	$0—	——
Increase Decrease In Deposits And Other Assets	-$279K-1,760%	-$15K+98.6%	-$1.08M—	——
Increase (Decrease) in Inventories	$36.23M+1,456%	-$2.67M-128%	$9.63M-75.0%	$38.56M-10.7%
Other liabilities	-$1.28M-11.8%	-$1.14M-44.6%	-$791K-57.6%	-$502K-329%
Increase (Decrease) in Prepaid Expense and Other Assets	——	——	$239K—	——
Interest income and other, net	——	——	——	——
Interest Paid, Excluding Capitalized Interest, Operating Activity	$9.08M-14.9%	$10.67M-40.9%	$18.05M—	——
Inventory Write Down	——	——	——	——
Cash Provided by (Used in) Financing Activity, Including Discontinued Operation	-$44.07M+24.4%	-$58.3M-49.5%	-$38.99M—	——
Cash Provided by (Used in) Investing Activity, Including Discontinued Operation	-$21.89M-155%	-$8.58M-72.2%	-$4.98M+64.2%	-$13.91M-3.0%
Cash Provided by (Used in) Operating Activity, Including Discontinued Operation	$50.4M-57.5%	$118.67M+1,249%	$8.8M+115%	-$59.51M+47.0%
Noncash Proceedsfrom Saleof Assets Previously Heldfor Sale	——	——	——	——
Number Of Batches In Production At The Time Of Disruption	——	——	——	——
Number Of FDA Approved Product	——	——	——	——
Number Of FDA Licensed Plasma Collection Facilities	——	——	——	——
Number of operating segments	——	——	——	——
Number Of Plasma Collection Facilities Under Development	——	——	——	——
Number of reportable segments	2—	——	——	——
Occupancy and Related Charges	$2.4M0.0%	$2.4M0.0%	$2.4M—	——
Operating Lease Incremental Borrowing Rate Percent	——	——	——	——
Operating Lease Payments	$2.4M0.0%	$2.4M0.0%	$2.4M—	——
Other income, net (Note 6)	-$210K-8.8%	-$193K+32.5%	-$286K+55.0%	-$635K-152%
Paid-in-kind interest capitalized	$0—	$0-100%	$3.84M—	——
Payments for Repurchase of Common Stock	——	——	$0—	——
Payments Of Debt Issuance Cost	$2.24M—	$0—	$0—	——
Payments of Financing Costs	$0—	$0-100%	$2.35M—	——
Payments to Acquire Intangible Assets	$316K-11.2%	$356K+69.5%	$210K—	$0—
Payments to Acquire Property, Plant, and Equipment	$22.58M+174%	$8.23M+72.4%	$4.77M-65.7%	$13.91M+3.0%
Proceeds From Insurance Settlement Operating Activities	——	——	——	——
Expected sale proceeds	——	——	——	——
Cash received from option exercises	$2.98M-60.2%	$7.49M+579%	$1.1M—	——
Restoration Costs Received	——	$200K0.0%	$200K—	——
Revenue From Contract With Customer Excluding Assessed Tax	$510.17M+19.6%	$426.45M+65.2%	$258.22M+67.6%	$154.08M+90.4%
Stock-based compensation	$20.03M+47.1%	$13.62M+120%	$6.19M+18.6%	$5.22M+49.5%
State And Loc Income Tax Paid Stateand Localafter Refund Receivedal	——	——	——	——
Stock Issued During Period Value Cashless Exercise Of Warrants	-$1K—	$0—	$0—	——
Stock Issued During Period, Value, Stock Options Exercised	$2.98M-60.2%	$7.49M+579%	$1.1M—	——
Stock Repurchased During Period Shares	——	——	——	——
Purchase price	——	——	——	——
Taxes Paid On Vested Restricted Stock Units	$9.55M+92.1%	$4.97M+251%	$1.42M—	——
Treasury stock, value, acquired	$32.09M—	——	——	——
Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes Amount	-$9.55M-92.1%	-$4.97M-251%	-$1.42M—	——
Warrants Issued In Connection With Notes Payable	$0—	$0-100%	$5.6M—	——
EBIT	$191.44M+37.7%	$138.98M+542%	$21.63M+155%	-$39.37M+32.6%
EBITDA	$199.34M+35.9%	$146.68M+402%	$29.23M+191%	-$32.25M+39.0%
EBITDA	$199.34M+35.9%	$146.68M+402%	$29.23M+191%	-$32.25M+39.0%
EBITDA margin	39.1%+4.7pp	34.4%+23.1pp	11.3%+32.3pp	-20.9%+44.4pp
EBIT	$191.44M+37.7%	$138.98M+542%	$21.63M+155%	-$39.37M+32.6%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What are ADMA Biologics's profit margins?: Gross margin is 61.3% and operating margin is 42.1%, with a 32.4% net margin.
Where does ADMA Biologics's income statement data come from?: Every line is extracted from ADMA Biologics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.